Diagnosis and treatment of pre-diabetes 2 Objectives: To estimate rates of prevalence, diagnosis, and treatment of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT).
antihyperglycemics, specifically metformin, can delay or prevent progression to type 2 diabetes mellitus (9). Consequently, in 2005 the American Diabetes Association recommended the oral antihyperglycemic, metformin, and lifestyle modification for those with IFG and/or IGT (3). Those with IFG, IGT, or both are at greater risk for cardiovascular disease than those with normal glucose metabolism, though their glycometabolic abnormalities do not yet qualify for a diagnosis of type 2 diabetes mellitus (4,5,6,7,8). Since type 2 diabetes mellitus is associated with even greater cardiovascular risk than pre-diabetes, preventing type 2 diabetes mellitus may improve cardiovascular outcomes, regardless of the impact on other cardiovascular risk factors. The DPP has demonstrated that progression of IFG/IGT to type 2 diabetes mellitus can be prevented or delayed by lifestyle modification and pharmacological interventions (9) . No studies to date have quantified the combined prevalence of IFG and IGT, and their rates of diagnosis and treatment. In addition, no studies have examined the rates of adherence to these therapies. Using data obtained from a nationally representative sample of the US population three years after publication of the DPP (the National Health and Nutrition Examination Survey [NHANES] IV), we assessed the proportion of adults who met criteria for IFG/IGT, and A the proportion of IFG/IGT subjects who: 1) reported receiving a formal diagnosis from their physician; 2) reported having lifestyle modification or an oral hypoglycemic agent recommended; and 3) were actively doing lifestyle modification or using an oral hypoglycemic agent.
RESEARCH DESIGN AND METHODS:
Data Source: The NHANES (National Health and Nutrition Examination Survey) is a crosssectional survey of the health and nutrition of the non-institutionalized, household dwelling US population, conducted by the National Center for Health Statistics and by the Centers for Disease Control and Prevention (10,11). The survey consists of two components: the in-home interview and the mobile exam center, which performs several laboratory tests, including the fasting plasma glucose (FPG) test and the two-hour oral glucose tolerance test (OGTT). The in-home survey collects demographic and clinical information, including subject age, race, gender, medical history, therapy, and lifestyle variables, such the frequency and duration of exercise, and dietary habits. Population: NHANES collects data in 2-year cohorts since 1999. The 2005-2006 sample from NHANES IV, the most recent publicly available version, was used in this study. We restricted our analyses to the subsample that had morning examinations, since those are the only subjects who had valid FPG and OGTT testing. We also excluded from our analyses subjects age <18, those with diagnosed or undiagnosed diabetes mellitus, and those with a history of myocardial infarction.
Study Variables and Definitions:
The current ADA definition for IFG is blood glucose 100-125 mg/dl after an eight hour fast (12). When the IFG category was initially introduced by the ADA, IFG was defined as 110-125 mg/dl after fasting. In 2003, the ADA lowered the threshold of IFG. to better capture those who met WHO's criteria for IGT. WHO defines IGT as having a glucose level of 140-199 mg/dl two hours after a glucose load (13). We compare the estimates of the prevalence of pre-diabetes using the old and the new FBG criterion. Subjects were asked if their physicians have ever told them that they have "borderline diabetes, prediabetes, impaired fasting glucose, or impaired glucose tolerance." A prior diagnosis of pre-diabetes was considered to be a "yes" to any of the four terms. The ADA recommends metformin alone as the antihyperglycemic of choice based upon the DPP results. However, because NHANES does not indicate the class of antihyperglycemic used for IFG/IGT, we could only determine whether any antihyperglycemic medication was given. Lifestyle modification included either exercise, diet modification, or both. Subjects who averaged at least 30 minutes of vigorous or moderate activity daily for the previous 30 days were considered "compliant" with ADA recommendations for treatment of IFG/IGT (3). Vigorous activity was defined as activity that causes "heavy sweating or large increases in breathing or heart rate". Moderate activity was defined as activity that causes "moderate sweating or slight to moderate increases in breathing or heart rate". Subjects were asked if they maintained their activity levels over the last year relative to the last 30 days. Provider recommendation for diet modification included reporting either counseling to reduce weight or counseling to reduce fat/calorie intake, or both. NHANES did not indicate the chronological order of the physician recommendations and the actual change in exercise or diet, so it is not possible to determine if lifestyle behaviors changed in response to recommendations. Statistical Analyses: The associations between subject demographics and medical conditions and the presence of pre-diabetes were examined using the chi-squared statistic for categorical predictor variables and logit modeling for continuous predictor variables. Sampling weights were used to provide estimates that are representative of the US population; all percentages presented are weighted. Most variables analyzed had little missing data (< 4%), but 16.7% of subjects were missing data for either income, education or both. Therefore, multiple imputation was used to more accurately account for the high level of missing data for all analyses involving these two variables (14). Multivariable logistic regression was used to examine independent predictors of treatment and adherence to lifestyle modification therapies. Independent variables in the model included gender, race, education, insurance status, and the percent of poverty level. All statistical analyses were performed using the STATA software (version 10.0, StataCorp LP, College Station, Texas).
RESULTS

Study Population. The NHANES 2005-2006
cohort included 2,425 subjects 18 or older in the morning examination (fasting) sample. From this sample, 878 were excluded from our analysis: 87 because they had had a prior MI (since we were interested in pre-diabetes and diabetes as CAD risk factors), 659 because they had missing OGTT data; 16 because they had diagnosed diabetes, and 116 because they had undiagnosed diabetes (based upon FPG and/or OGTT testing). Subjects who were on oral medications or receiving insulin for their diagnosed diabetes were excluded from OGTT testing; hence only 16 subjects were excluded for diagnosed diabetes and 116 for undiagnosed diabetes. These exclusions resulted in a sample of 1,547 subjects in the study. Applying sample weights to make results representation of the non-diabetic US population without a history of myocardial infarction, we estimate that about 34.6% (CI 30.3-38.9%) of non-diabetic American adults had pre-diabetes. Of the prediabetes subjects, 84% met IFG criteria, 44% met IGT criteria, and 28% met both. Using the 1997 ADA criteria for IFG (110-125mg/dl) resulted in 43% fewer subjects meeting criteria for IFG, reducing the estimate of the prevalence of pre-diabetes in non-diabetic American adults from 34.6% to 19.8% (Table 1) . Demographics and medical conditions. The subjects' demographic characteristics and medical conditions are reported in Table 2 . Those with pre-diabetes subjects had substantially higher cardiovascular risk, having a mean Framingham 10-year risk for cardiovascular events of 8.5% (CI, 6.0-10.6%), which was almost twice that of normoglycemic subjects (5.2% [CI, 3.9-6.4%], p<0.001) (15,16). Only 3.4% of the entire study sample reported a prior diagnosis of "impaired fasting glucose, impaired glucose tolerance, borderline diabetes, or prediabetes" (Table 2) . Of those reporting a diagnosis, 38.5% no longer met pre-diabetes criteria (either due to resolution or misdiagnosis); 61.5% had unresolved prediabetes. No diagnosed pre-diabetes subjects reported receiving oral antihyperglycemic medications (CI, 0-10.8%). Multivariable analysis found that subjects who had prediabetes tended to be older, male, and Mexican-American (Table 3) . Subject-reports of recommendations for and practice of diabetes prevention behaviors. Of pre-diabetes subjects, 31.7% (CI, 23.3-40.2%) reported receiving counseling for exercise, 33.4% (CI, 26.4-40.5%) for diet, and 25.9% (CI, 17.9-34.5%) for both (Table 4) . Of those who reported exercising, only about half reported achieving the ADA IFG/IGT guidelines of at least 30 minutes daily. Rates of recommendations for and practice of diabetes prevention behaviors were similar when the 1997 ADA criteria for IFG (fasting plasma glucose of 110-125) were applied.
DISCUSSION
This study is the first to publish a combined estimate of IFG/IGT in a national sample, and the first to explore its contemporary diagnosis and treatment patterns. Using NHANES data gathered roughly three years after the publication of the DPP, we found that the majority of people with IFG and/or IGT are undiagnosed and untreated with interventions that the DPP suggests can substantially reduce progression to type 2 diabetes mellitus, reducing the risk of both microvascular and macrovascular complications. Delays in the adoption of effective new therapies have been commonly reported. However, given the significant potential benefits of metformin and lifestyle modification, the very low level of detection and intervene are concerning. In the DPP randomized trial, lifestyle modification and metformin reduced the incidence of type 2 diabetes mellitus by 58% and by 38%, respectively, in just three years (15,16, 17). We found similar rates of prevalence of IFG and IGT as reports from earlier time periods (1, 2) and found a combined prevalence of 34.6% non-diabetic American adults. Consistent with prior studies, relative to normoglycemic subjects, pre-diabetes subjects in this cohort tended to be older, male, Mexican-American, hypertensive, hyperlipidemic, and have substantially greater overall 10-year cardiovascular risk. Disappointingly, only 3.4% of pre-diabetes people reported that their physicians diagnosed them with pre-diabetes. This extremely low rate could in part be due to incomplete recollection by subjects, or because physicians did not emphasize the importance of pre-diabetes to their patients. Another likely explanation is that physicians do not adequately screen for and diagnose pre-diabetes, resulting in marked underdiagnosis of pre-diabetes. For instance, physicians did not recommend lifestyle modification to pre-diabetes subjects any more intensively than normoglycemic subjects. In addition, not one subject reported receiving metformin, suggesting that physicians were either unaware of metformin's benefits, were hesitant to prescribe, or were unaware the subject had pre-diabetes; however, it is also possible that many physicians are aware of the DPP findings, but found its results unconvincing. Three years after the DPP, however, subjects reported that lifestyle interventions were recommended to less than a third of prediabetes subjects. Of pre-diabetes subjects, less than half reported exercising, less than two-thirds reported recent attempts at weight and/or diet control, and 44 % reported both. Though it could be argued that the recent formal guidelines may improve upon practice at the time of study (our NHANES cohort was from 2005-2006 and US Preventive Services Task Force and ADA guidelines were published around this time), most evidence suggests that passive dissemination of national guidelines is ineffective in changing clinical practice. While substantial evidence has demonstrated the benefits of early glycemic control in reducing the incidence of type 2 diabetes mellitus, whether early glycemic control significantly reduces cardiovascular outcomes has been debated. However, unlike most studies of early or intensive antihyperglycemic medication interventions, intervention with a lifestyle modification intervention in pre-diabetes substantially improved cardiovascular risk factors in the DPP (such as blood pressure and lipids), making it likely that such interventions will improve cardiovascular outcomes (18). It is also possible that lowering the lifetime glycemic burden by early intervention could reduce long-term cardiovascular outcomes, such as that seen in the 17 year follow-up of the DCCT trial (19). Finally, the cardiovascular risk associated with overt type 2 diabetes mellitus is substantially greater than cardiovascular risk associated with prediabetes, suggesting that delaying or preventing type 2 diabetes mellitus should improve both cardiovascular and microvascular outcomes, regardless of the direct impact on other cardiovascular risk factors (20). The limitations of our study include large amounts of missing data for smoking, particularly when calculating the Framingham risk score. In addition, rates of physician diagnosis were subject to subject self-report and were not verified by chart abstraction; consequently the rates of diagnosis and treatment of IFG/IGT may have been underreported. Also, only subjects reporting pre-diabetes were asked about whether they were on oral hypoglycemic medications, so some additional subjects may have been treated that were not captured in our results. NHANES also does not report the chronological order of diagnosis, recommendation, and treatment. Finally, the ADA 2003 criteria for IFG resulted in a dramatic increase in the number of people being diagnosed with IFG and has been controversial; many physicians may disagree with this lower threshold for diagnosis. However, the 20% of the population who met 1997 ADA pre-diabetes criteria had similar results of recommendation and compliance with lifestyle modification measures as did those who met the new ADA pre-diabetes criteria.
CONCLUSION
Three years after a landmark study demonstrated that early diagnosis of and intervention of pre-diabetes can substantially reduce progression to type 2 diabetes mellitus, the majority of people with IFG and/or IGT were undiagnosed and untreated. Whether this is due to physicians being unaware of the evidence, unconvinced by the evidence, or clinical inertia is unclear. Consideration should be given to national policies to improve upon this situation, such as public and provider education programs.
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